ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2244

Diagnostic Accuracy Of Anti-Ccp Testing For Detecting Prevalent Rheumatoid Arthritis: Results From Screening a  Population Based Cohort

Aase Haj Hensvold1, Patrik KE Magnusson2, Lena Israelsson3, Monika Hansson4, Vijay Joshua1, Rikard Holmdahl5, Per-Johan Jakobsson3, Johan Askling6, Vivianne Malmström7, Lars Klareskog3 and Anca I Catrina3, 1Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 2Medical Epidemiology and Biostatistics, Swedish Twin Registry Karolinska Institutet, Stockholm, Sweden, 3Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 4Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 5Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, 6Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 7Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: ACPA

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis-Clinical Aspects III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Anti-CCP testing is a part of the clinical routine investigations for rheumatoid arthritis (RA). Previous studies have relative few included controls per patients. We therefor aimed to screen a large population-based cohort and investigate the diagnostic accuracy of testing anti-CCP, in high concentration, and testing of other ACPAs, for detecting RA.

Methods:

We used a subset of the Swedish twin registry, which includes 12 590 monozygotic and dizygotic twins born 1958 or earlier (median age 65, range 48-93). Cases of RA were identified by linkage to the Swedish National Patient Register and by this way we defined clinical RA as the reference standard when analyzing the diagnostic accuracy. Blood samples were analyzed for Anti-CCP2 using Immunscan CCPlus (Eurodiagnostica). Cut off set by the manufacture were used to define positive (≥cut off), and high positive (>3x cut off) CCP was defined in accordance to EULAR criteria for RA. All Anti-CCP positive samples were further investigated by ELISA for the presence of antibodies against autoantigen-derived citrullinated peptides (alpha-enolase: aa5-21; collagen type II: aa359-369; fibrinogen: aa563-583 and vimentin: aa60-75). Sensitivity and specificity as well as the positive (PPV) and negative (NPV) predictive values of Anti-CCP testing for detecting prevalent RA were estimated.

Results:

350 out of 12 590 tested individuals (2.8%) were positive for Anti-CCP. 1.5% (192/12590) had prevalent RA with in median 5 years from first occurring RA diagnosis in register to blood donation. Of these RA cases, 65% (124/192) were positive for Anti-CCP and a majority had high concentrations (93%). The rest of those positive for Anti-CCP were without RA diagnosis and fewer had high positive anti-CCP (39%).

The sensitivity and specificity for high positive Anti-CCP testing were 60% (95% CI: 53-67%) and 99% (95% CI: 99%), respectively. Both high positive Anti-CCP and Anti-CCP had a good predictive value for detecting RA (PPV 57%, 95% CI 50-64% for high positive Anti-CCP and 35%, 95% CI 30-40% for Anti-CCP) and a negative predictive values close to 100%.

Anti-CEP1 antibodies were the most common ACPA among Anti-CCP positive RA patients and Anti-CCP positive without RA. There was a correlation between anti-ccp concentration and occurrence other ACPAs (Spearman Correlation Coefficient r= 0.75 p <0.0001). In accordance we found 52% sensitivity for positive anti-CCP2 test and ≥1 other ACPA test positive and 99% specificity, PPV was 56% and the NPV was 99%

Conclusion:

Anti-CCP testing has a good diagnostic accuracy for RA in a large population based cohort. Anti-CCP in high concentration is correlated with presence of other ACPAs in population based cohort. A follow up study to identify new incident cases of RA among tested individuals will allow more accurate estimates in the future.


Disclosure:

A. H. Hensvold,
None;

P. K. Magnusson,
None;

L. Israelsson,
None;

M. Hansson,
None;

V. Joshua,
None;

R. Holmdahl,
None;

P. J. Jakobsson,
None;

J. Askling,

AstraZeneca,

2,

AstraZeneca,

5;

V. Malmström,
None;

L. Klareskog,
None;

A. I. Catrina,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diagnostic-accuracy-of-anti-ccp-testing-for-detecting-prevalent-rheumatoid-arthritis-results-from-screening-a-population-based-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies